Research Article
Volume 5 Issue 2 - 2021
Ultralong Analogue Insulin Degludec in Type 1 Diabetes: Reduction of Hypoglycemic Events
Lilian Sanhueza1*, Pilar Durruty2 and Manuel García de los Ríos3
1Associated Professor, Faculty of Medical Sciences, University of Santiago of Chile, Santiago, Chile
2Associated Professor, Faculty of Medicine, University of Chile, Santiago, Chile
3Titular Professor, Faculty of Medicine, University of Chile, Santiago, Chile
*Corresponding Author: Lilian Sanhueza, Associated Professor, Faculty of Medical Sciences University of Santiago of Chile, Santiago, Chile.
Received: December 16, 2020; Published: January 20, 2021


Long-acting insulins analogues are related with the reduction of hypoglycemic events.

Objective: Ultralong-acting insulin analog Degludec (IDeg) in type 1 diabetic patients (T1D) previously treated with Glargine (U-100) with severes hypoglycemic events and poor metabolic control.

Patients and Method: 230 T1D patients were followed for 18 months, average 34 years old and 14 years of the diabetes diagnosed. Hypoglycemias, biochemical parameters and insulin requirements were analyzed in a period of 18 months. All the patients were on a basal bolus regimen with IDeg as basal adjusted fortnightly, and ultra-fast bolus insulin pre-meals three times a daily.

Results: At 3 months fasting glycemia decreased from 253 mg/dl to 180 mg/dl; at 6 months 156 mg/dl; at 12 months151 mg/dl and at 18 months 150 mg/dl. Glycated hemoglobin (HbA1c) initially 10.6%, decreased at 3 months to 8.7% at 6 months 8.3% at 12 months 9.0%, at 18 months 9.0%. All these results were statistically significant p < 0.05. Hypoglycemic events, milds, moderate, severes, and nocturnal, decreased significantly throughout the study, improving the quality of life of patients

Conclusion: IDeg in T1D showed to reduce fasting glycemia, HbA1c, and hypoglycemic events.

 Keywords: Clinical Parameters; Fasting Glycemia; Metabolic Control


    1. Simó R. “Nueva insulina basal de acción ultralenta: insulina degludec”. Avances en Diabetologia 29 (2013): 4-11.
    2. Muñoz M. “Degludec, una nueva insulina basal de acción ultra-lenta para el tratamiento de la diabetes tipo 1 y 2: avances en investigación clínica”. Endocrinología y Nutrición 61 (2014): 153-159.
    3. Vora J., et al. “Clinical use of insulin degludec”. Diabetes Research and Clinical Practice 109 (2015): 19-31.
    4. Berard L and MacNeill G. “Insulin degludec, a long-acting-daily basal analogue for type 1 and type 2 diabetes mellitus”. Canadian Journal of Diabetes 39 (2015): 4-9.
    5. Yamamoto C., et al. “Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus”. Endocrine Journal 63(2016): 53-60.
    6. Heise T., et al. “Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action”. Diabetes 8 (2016): 132-138.
    7. Birkeland KI., et al. “Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine”. Diabetes Care 34 (2011): 661-665.
    8. Sanhueza L., et al. “Experiencia con insulina degludec en pacientes diabéticos tipo 1 del Hospital San Juan de Dios, Santiago, Chile”. Revista Chilena de Endocrinología y Diabetes 10 (2017): 131-136.
    9. Dzygalo K., et al. “The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials”. Acta Diabetology 52 (2015): 231-238.
    10. Lane W., et al. “Effect of degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes. The SWITCH 1 randomized clinical trial”. JAMA 318 (2017): 33-44.
    11. Vora J., et al. “Insulin degludec versus Insulin Glargine in type 1 and type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials”. Diabetes Therapy 5 (2014): 435-446.
    12. Heller S., et al. “Insulin Degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal Bolus Type1): A phase 3, randomised, open-label, treat-to-target, non-inferiority trial”. Lancet 379 (2012): 1489-1497.
    13. Nakae R., et al. “Medium-Term “Effects of Insulin Degludec on Patients with Type 1 Diabetes Mellitus”. Drugs 14 (2014): 133-138.
    14. Ratner RE., et al. “Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials”. Diabetes, Obesity and Metabolism 15 (2013): 175-184.
    15. Gold AE., et al. “Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia”. Diabetes Care 17 (1994): 697-703.
    16. Koehler G., et al. “Insulin degludec is not associated with a delayed or diminished response hypoglycemia compared with insulin glargine in type 1 diabetes: a double-blind randomized crossover study”. Diabetologia 47 (2014): 40-49.
    17. Home PD., et al. “Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes”. Diabetes Medicine 29 (2012): 716-720.
    18. Woodward A., et al. “Nocturnal hypoglycemia in type 1 diabetes-frecuency and predictive factors”. QJM 102 (2009): 603-607.
    19. Lane W., et al. “Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients with Type 1 Diabetes. The SWITCH 1 Randomized Clinical Trial”. JAMA 318 (2017): 33-44.
    20. Karamat MA., et al. “Clinical and Cost Implications of Insulin Degludec in Patients with Type 1 Diabetes and Problematic Hypoglycemia: A Quality Improvement Proyect”. Diabetes Therapy 9 (2018): 839-849.
    21. Pollock RF and Tikkanen CK. “A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark”. Journal of Medical Economics 20 (2017): 213-220.
Citation: Lilian Sanhueza., et al. “Ultralong Analogue Insulin Degludec in Type 1 Diabetes: Reduction of Hypoglycemic Events”. EC Diabetes and Metabolic Research 5.2 (2021): 08-14.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

November Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 14, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.